NCT02228265View on ClinicalTrials.gov

Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

CompletedOBSERVATIONAL
Enrollment

41

Participants

Timeline

Start Date

March 12, 2013

Primary Completion Date

October 1, 2019

Study Completion Date

February 27, 2020

Conditions
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaProstate AdenocarcinomaPSA ProgressionRecurrent Prostate CarcinomaStage IV Prostate Cancer
Interventions
OTHER

Cytology Specimen Collection Procedure

Undergo blood and tissue collection

DRUG

Enzalutamide

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (3)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

94115

UCSF Medical Center-Mount Zion, San Francisco

97239

OHSU Knight Cancer Institute, Portland

All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Oregon Health and Science University

OTHER

lead

OHSU Knight Cancer Institute

OTHER

NCT02228265 - Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide | Biotech Hunter | Biotech Hunter